Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Growth Hormone Treatment in Short Children Born Small for Date (Genotonorm)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00174408

Enrollment

110

Registered

2005-09-15

Start date

1990-03-31

Completion date

2005-02-28

Last updated

2007-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Disorders

Brief summary

The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)

Interventions

DRUGGenotropin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 7 Years

Healthy volunteers

Inclusion criteria

* Birth length below -2 SD * Height at start below - 2 Sd

Exclusion criteria

* Any endocrine or chronic disease * Any known syndrome with short stature

Design outcomes

Primary

Measure	Time frame
Height, height velocity	—

Secondary

Measure	Time frame
Side effects	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026